Opinion
Civil Action 21-13087 (JXN) (JSA) 22-1232 (JXN) (JSA)
12-19-2024
MYLAN PHARMACEUTICALS INC., Plaintiff, v. TEVA PHARMACEUTICALS INDUSTRIES LTD, TEVA PHARMACEUTICALS USA, INC., TEVA NEUROSCIENCE, INC., AND TEVA SALES & MARKETING, INC., Defendants. In re: COPAXONE ANTITRUST LITIGATION This documents relates to: All Actions
(COORDINATED FOR DISCOVERY PURPOSES ONLY) ORDER
Jessica S. Allen United States Magistrate Judge
THIS MATTER having come before the Court by way of the parties' joint status letter filed on November 18, 2024, wherein the parties set forth their scheduling disputes in Mylan Pharms. Inc. v. Teva Pharms. Indus. Ltd., Civ. No. 21-13087 (JXN) (JSA) (“Mylan Action”), (ECF No. 154), and in In re: Copaxone Antitrust Lit., Civ. No. 22-1232 (JXN) (JSA) (“In re Copaxone Matter”), (ECF No. 122);
and it appearing that the court-appointed Special Master, the Honorable Faith S. Hochberg U.S.D.J. (Ret.), issued a Report and Recommendation dated November 25, 2024, in which Judge Hochberg recommended a specific case schedule, (see Report and Recommendation, at 5-6);
and it appearing that neither Defendants nor Plaintiffs have filed any objections to the Report and Recommendation; and it appearing that for the reasons set forth in Judge Hochberg's Report and Recommendation;
IT IS SO ORDERED
ORDERED that Judge Hochberg's Report and Recommendation dated November 25, 2024, is ADOPTED.